Lantern to Join Forces with Califia for Launching Antibody Drug Conjugate Program
shot by IP News Shots / 6:23 pm on 05 January, 2021
Lantern Pharma, Inc. and Califia Bio, Inc. are set to work on the launch of an Antibody Drug Conjugate (ADC) program through an evaluation and potential development agreement. “Notably, Lantern will possibly leverage the patented linker library, conjugation processes and payloads, etc., for development as ADC-based therapies. “Additionally, Lantern will make use of its AI platform RADR to identify the cancer types, targets, and biomarker signatures that are anticipated to respond to and benefit from ADC approach.
Read More at: https://www.biospace.com/article/releases/lantern-pharma-announces-launch-of-antibody-drug-conjugate-adc-program-to-target-solid-tumors-and-amp-blood-cancers-through-agreement-with-califia-pharma/